Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IDE892 + RG6620
- Development stage
- Unknown
- Lead developer
- Genentech
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
IDE892 + RG6620 (GDC-7035) is an investigational combination therapy being evaluated for the treatment of pancreatic ductal adenocarcinoma (PDAC) harboring both a methylthioadenosine phosphorylase (MTAP) deletion and a KRAS G12D mutation. IDE892 is a highly selective, methylthioadenosine (MTA)-cooperative inhibitor of protein arginine methyltransferase 5 (PRMT5) developed by IDEAYA Biosciences. It selectively binds to PRMT5 in the presence of MTA, exploiting the synthetic lethal vulnerability created by MTAP deletion in tumor cells. RG6620 (GDC-7035), developed by Genentech (a member of the Roche Group), is a selective small molecule inhibitor of the KRAS G12D mutant protein. By combining PRMT5 inhibition with KRAS G12D pathway blockade, this therapeutic regimen aims to deliver deeper and more durable anti-tumor responses in a molecularly defined patient population that currently lacks approved targeted treatment options.
- Other names
- GDC-7035 + IDE892IDE892 + GDC-7035IDE892 + RG6620RG6620 + IDE892
02
Targets
KRASG12D (Kirsten rat sarcoma viral oncogene homolog (KRAS) G12D mutant)PRMT5 (Protein arginine N-methyltransferase 5)
Beyond the preview
Go deeper on IDE892 + RG6620.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IDE892 + RG6620.